Basilea Pharmaceutica (XSWX:BSLN) ROCE %: 25.01% (As of Dec. 2025)


XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
59 GF Score
Price CHF54.70
GF Value CHF57.66
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica ROCE %?

Basilea Pharmaceutica XSWX:BSLN -0.55% 59 ROCE % is 25.01% as of Dec. 2025. GuruFocus rates XSWX:BSLN with a GF Score™ of 59/100 and a GF Value™ of CHF57.66 (Fairly Valued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Basilea Pharmaceutica's annualized ROCE % for the quarter that ended in Dec. 2025 was 25.01%.

Basilea Pharmaceutica  (XSWX:BSLN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Basilea Pharmaceutica ROCE % Related Terms

Basilea Pharmaceutica ROCE % Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica ROCE % Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.07 20.06 15.95 38.24 22.13

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.18 14.24 60.32 19.94 25.01
XSWX:BSLN
59GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica ROCE % Calculation

Basilea Pharmaceutica's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=49.232/( ( (257.764 - 45.558) + (281.999 - 49.216) )/ 2 )
=49.232/( (212.206+232.783)/ 2 )
=49.232/222.4945
=22.13 %

Basilea Pharmaceutica's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=55.926/( ( (248.847 - 34.393) + (281.999 - 49.216) )/ 2 )
=55.926/( ( 214.454 + 232.783 )/ 2 )
=55.926/223.6185
=25.01 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 25.01% mean?
Basilea Pharmaceutica (XSWX:BSLN) has a ROCE % of 25.01% as of Dec. 2025.
Is Basilea Pharmaceutica's ROCE % too high?
Basilea Pharmaceutica's current ROCE % is 25.01%. Overall, Basilea Pharmaceutica has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's ROCE % compare to VRTX and REGN?
Basilea Pharmaceutica's ROCE % of 25.01% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Basilea Pharmaceutica's current ROCE % is 25.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.66, compared to a current price of CHF54.70 — trading 5.1% below its estimated fair value. The current ROCE % is 25.01%. Basilea Pharmaceutica's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current ROCE % is 25.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF54.70 is trading 5.1% below its estimated GF Value™ of CHF57.66. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for XSWX:BSLN:

  • ROCE %: 25.01%
  • GF Value™: CHF57.66 vs. price of CHF54.70 (5.1% below fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
59GF Score

Get the complete analysis for XSWX:BSLN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF54.70
Price
CHF57.66
GF Value